Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Glioblastoma 107Gliosarcoma 48Glioma 41Brain Neoplasms 38Astrocytoma 38Central Nervous System Neoplasms 30Oligodendroglioma 27Medulloblastoma 15Melanoma 14Neuroblastoma 13Ependymoma 11Neoplasms 10Familial ependymoma 8Choroid Plexus Neoplasms 8Unspecified Adult Solid Tumor, Protocol Specific 6Sarcoma 6Optic Nerve Glioma 6Neuroectodermal Tumors, Primitive 6Neoplasm Metastasis 6Sarcoma, Ewing 5Recurrence 5Rhabdoid Tumor 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Osteosarcoma 4Lymphoma 4Glioma, Subependymal 4Spinal Cord Neoplasms 3Rhabdomyosarcoma 3Pinealoma 3

Interventions

temsirolimus 1Vorinostat 1Vinorelbine 1Temozolomide 1Sirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Paraganglioma, Extra-Adrenal × Temozolomide × Clear all
NCT01076530 2013-05-03

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSEndocrine

Familial ependymoma, Astrocytoma, Medulloblastoma, Oligodendroglioma, Paraganglioma, Extra-Adrenal, Spinal Cord Neoplasms, Choroid Plexus Neoplasms, Rhabdoid Tumor, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡